Patient cohort demographics demonstrating statistical significance in comparison of patient age, hospital site and trending toward significance for neuropathy
| Healing | No | Yes | P value |
| n | 58 | 65 | |
| Site (%) | |||
| Center A | 38 (65.5) | 29 (44.6) | |
| Center B | 20 (34.5) | 36 (55.4) | 0.032 |
| Sex (%) | |||
| Male | 48 (82.8) | 47 (72.3) | 0.244 |
| Age, mean (SD) | 71.1 (12.5) | 65.3 (11.9) | 0.01 |
| DM type (%) | |||
| Type 1 | |||
| Type 2 | 55 (94.8) | 56 (86.2) | 0.189 |
| DM duration, years, mean (SD) | 17.2 (14.1) | 18.8 (11.9) | 0.506 |
| Smoking (%) | 0.299 | ||
| Current | 4 (6.9) | 10 (15.4) | |
| Non-smoker | 25 (43.1) | 23 (35.4) | |
| Previously smoked | 29 (50.0) | 32 (49.2) | |
| Ischemic heart disease (%) | |||
| Yes | 14 (24.1) | 14 (21.5) | 0.898 |
| Retinopathy (%) | |||
| Yes | 22 (37.9) | 26 (40.0) | 0.96 |
| Renal failure (%) | |||
| Yes | 13 (22.4) | 10 (15.4) | 0.443 |
| Stroke (%) | |||
| Yes | 11 (19.0) | 12 (18.5) | 1 |
| Heart failure (%) | |||
| Yes | 4 (6.9) | 4 (6.2) | 1 |
| Minor amputation history (%) | |||
| Yes | 13 (22.4) | 15 (23.1) | 1 |
| Major amputation history (%) | |||
| Yes | |||
| No | 58 (100.0) | 65 (100.0) | NA |
| Antiplatelet therapy (%) | |||
| Yes | 40 (69.0) | 37 (56.9) | 0.234 |
| Statins (%) | |||
| Yes | 46 (79.3) | 56 (86.2) | 0.443 |
| Neuropathy (%) | |||
| Yes | 53 (91.4) | 50 (76.9) | 0.054 |
| Gangrene (%) | |||
| Yes | 11 (19.0) | 5 (7.7) | 0.113 |
| Texas grade (%) | 0.176 | ||
| 0 | 1 (1.7) | 0 (0.0) | |
| 1 | 31 (53.4) | 46 (70.8) | |
| 2 | 5 (8.6) | 5 (7.7) | |
| 3 | 21 (36.2) | 14 (21.5) | |
| Texas stage (%) | 0.508 | ||
| A | 14 (24.1) | 20 (30.8) | |
| B | 17 (29.3) | 23 (35.4) | |
| C | 8 (13.8) | 8 (12.3) | |
| D | 19 (32.8) | 14 (21.5) |
*Figures in bold denot significant values (p<0.05)
DM, diabetes mellitus; NA, not available.